Citigroup Trims Eiger BioPharmaceuticals (NASDAQ:EIGR) Target Price to $3.00
Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Free Report) had its price objective decreased by Citigroup from $4.00 to $3.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Citigroup’s target price would suggest a potential upside of 266.88% from the stock’s current price. EIGR has […]